With great interest, we read Li and colleagues’ article¹ in this issue of JAMA Surgery. The authors sought to compare the short-term outcomes of laparoscopic distal gastrectomy with those of open distal gastrectomy for the treatment of patients with locally advanced (cT2-4aN+M0) distal gastric cancer. In this study, an open-label, single center, phase 2 randomized clinical trial with a noninferiority design, the authors assessed outcomes at 3 years. All patients received neoadjuvant therapy of oxaliplatin and capecitabine before their operation. Li and colleagues¹ reported significantly lower postoperative complication rates, less postoperative pain, and better adherence to and completion of adjuvant therapy among trial participants.

怀着极大的兴趣，我们阅读了Li及其同事在本期JAMA Surgery中的文章¹。作者试图比较腹腔镜远端胃切除术和开放远端胃切除术治疗局部晚期（cT2-4aN + M0）远端胃癌患者的近期疗效。在这项研究中，采用非劣效设计的开放标签，单中心，2期随机临床试验，作者评估了3年的结果。所有患者术前均接受了奥沙利铂和卡培他滨的新辅助治疗。Li等[ ^1]报道，试验参与者的术后并发症发生率显着降低，术后疼痛减轻，辅助治疗的依从性和完成率更高。